Arianna Sala1,2, Camilla Caprioglio1, Roberto Santangelo3, Emilia Giovanna Vanoli4, Sandro Iannaccone5, Giuseppe Magnani3, Daniela Perani6,7,8. 1. Vita-Salute San Raffaele University, Milan, Italy. 2. In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy. 3. Department of Neurology and INSPE, San Raffaele Scientific Institute, Milan, Italy. 4. Nuclear Medicine Unit, San Raffaele Hospital, Via Olgettina 60, Milan, Italy. 5. Neurological Rehabilitation Unit, Clinical Neurosciences Department, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy. 6. Vita-Salute San Raffaele University, Milan, Italy. perani.daniela@hsr.it. 7. In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy. perani.daniela@hsr.it. 8. Nuclear Medicine Unit, San Raffaele Hospital, Via Olgettina 60, Milan, Italy. perani.daniela@hsr.it.
Abstract
PURPOSE: Given the challenges posed by the clinical diagnosis of atypical Alzheimer's disease (AD) variants and the limited imaging evidence available in the prodromal phases of atypical AD, we assessed brain hypometabolism patterns at the single-subject level in the AD variants spectrum. Specifically, we tested the accuracy of [18F]FDG-PET brain hypometabolism, as a biomarker of neurodegeneration, in supporting the differential diagnosis of atypical AD variants in individuals with dementia and mild cognitive impairment (MCI). METHODS: We retrospectively collected N = 67 patients with a diagnosis of typical AD and AD variants according to the IWG-2 criteria (22 typical-AD, 15 frontal variant-AD, 14 logopenic variant-AD and 16 posterior variant-AD). Further, we included N = 11 MCI subjects, who subsequently received a clinical diagnosis of atypical AD dementia at follow-up (21 ± 11 months). We assessed brain hypometabolism patterns at group- and single-subject level, using W-score maps, measuring their accuracy in supporting differential diagnosis. In addition, the regional prevalence of cerebral hypometabolism was computed to identify the most vulnerable core regions. RESULTS: W-score maps pointed at distinct, specific patterns of hypometabolism in typical and atypical AD variants, confirmed by the assessment of core hypometabolism regions, showing that each variant was characterized by specific regional vulnerabilities, namely in occipital, left-sided, or frontal brain regions. ROC curves allowed discrimination among AD variants and also non-AD dementia (i.e., dementia with Lewy bodies and behavioral variant of frontotemporal dementia), with high sensitivity and specificity. Notably, we provide preliminary evidence that, even in AD prodromal phases, these specific [18F]FDG-PET patterns are already detectable and predictive of clinical progression to atypical AD variants at follow-up. CONCLUSIONS: The AD variant-specific patterns of brain hypometabolism, highly consistent at single-subject level and already evident in the prodromal stages, represent relevant markers of disease neurodegeneration, with highly supportive diagnostic and prognostic role.
PURPOSE: Given the challenges posed by the clinical diagnosis of atypical Alzheimer's disease (AD) variants and the limited imaging evidence available in the prodromal phases of atypical AD, we assessed brain hypometabolism patterns at the single-subject level in the AD variants spectrum. Specifically, we tested the accuracy of [18F]FDG-PET brain hypometabolism, as a biomarker of neurodegeneration, in supporting the differential diagnosis of atypical AD variants in individuals with dementia and mild cognitive impairment (MCI). METHODS: We retrospectively collected N = 67 patients with a diagnosis of typical AD and AD variants according to the IWG-2 criteria (22 typical-AD, 15 frontal variant-AD, 14 logopenic variant-AD and 16 posterior variant-AD). Further, we included N = 11 MCI subjects, who subsequently received a clinical diagnosis of atypical ADdementia at follow-up (21 ± 11 months). We assessed brain hypometabolism patterns at group- and single-subject level, using W-score maps, measuring their accuracy in supporting differential diagnosis. In addition, the regional prevalence of cerebral hypometabolism was computed to identify the most vulnerable core regions. RESULTS: W-score maps pointed at distinct, specific patterns of hypometabolism in typical and atypical AD variants, confirmed by the assessment of core hypometabolism regions, showing that each variant was characterized by specific regional vulnerabilities, namely in occipital, left-sided, or frontal brain regions. ROC curves allowed discrimination among AD variants and also non-ADdementia (i.e., dementia with Lewy bodies and behavioral variant of frontotemporal dementia), with high sensitivity and specificity. Notably, we provide preliminary evidence that, even in AD prodromal phases, these specific [18F]FDG-PET patterns are already detectable and predictive of clinical progression to atypical AD variants at follow-up. CONCLUSIONS: The AD variant-specific patterns of brain hypometabolism, highly consistent at single-subject level and already evident in the prodromal stages, represent relevant markers of disease neurodegeneration, with highly supportive diagnostic and prognostic role.
Authors: H A Middelkoop; W M van der Flier; E J Burton; A J Lloyd; S Paling; R Barber; C Ballard; I G McKeith; J T O'Brien Journal: Neurology Date: 2001-12-11 Impact factor: 9.910
Authors: Rik Ossenkoppele; Yolande A L Pijnenburg; David C Perry; Brendan I Cohn-Sheehy; Nienke M E Scheltens; Jacob W Vogel; Joel H Kramer; Annelies E van der Vlies; Renaud La Joie; Howard J Rosen; Wiesje M van der Flier; Lea T Grinberg; Annemieke J Rozemuller; Eric J Huang; Bart N M van Berckel; Bruce L Miller; Frederik Barkhof; William J Jagust; Philip Scheltens; William W Seeley; Gil D Rabinovici Journal: Brain Date: 2015-07-02 Impact factor: 13.501
Authors: Gil D Rabinovici; William J Jagust; Ansgar J Furst; Jennifer M Ogar; Caroline A Racine; Elizabeth C Mormino; James P O'Neil; Rayhan A Lal; Nina F Dronkers; Bruce L Miller; Maria Luisa Gorno-Tempini Journal: Ann Neurol Date: 2008-10 Impact factor: 10.422
Authors: Jeffrey S Phillips; Sandhitsu R Das; Corey T McMillan; David J Irwin; Emily E Roll; Fulvio Da Re; Ilya M Nasrallah; David A Wolk; Murray Grossman Journal: Hum Brain Mapp Date: 2017-11-06 Impact factor: 5.038
Authors: Katya Rascovsky; John R Hodges; David Knopman; Mario F Mendez; Joel H Kramer; John Neuhaus; John C van Swieten; Harro Seelaar; Elise G P Dopper; Chiadi U Onyike; Argye E Hillis; Keith A Josephs; Bradley F Boeve; Andrew Kertesz; William W Seeley; Katherine P Rankin; Julene K Johnson; Maria-Luisa Gorno-Tempini; Howard Rosen; Caroline E Prioleau-Latham; Albert Lee; Christopher M Kipps; Patricia Lillo; Olivier Piguet; Jonathan D Rohrer; Martin N Rossor; Jason D Warren; Nick C Fox; Douglas Galasko; David P Salmon; Sandra E Black; Marsel Mesulam; Sandra Weintraub; Brad C Dickerson; Janine Diehl-Schmid; Florence Pasquier; Vincent Deramecourt; Florence Lebert; Yolande Pijnenburg; Tiffany W Chow; Facundo Manes; Jordan Grafman; Stefano F Cappa; Morris Freedman; Murray Grossman; Bruce L Miller Journal: Brain Date: 2011-08-02 Impact factor: 13.501
Authors: Sebastian J Crutch; Manja Lehmann; Jonathan M Schott; Gil D Rabinovici; Martin N Rossor; Nick C Fox Journal: Lancet Neurol Date: 2012-02 Impact factor: 44.182
Authors: Sebastian J Crutch; Jonathan M Schott; Gil D Rabinovici; Melissa Murray; Julie S Snowden; Wiesje M van der Flier; Bradford C Dickerson; Rik Vandenberghe; Samrah Ahmed; Thomas H Bak; Bradley F Boeve; Christopher Butler; Stefano F Cappa; Mathieu Ceccaldi; Leonardo Cruz de Souza; Bruno Dubois; Olivier Felician; Douglas Galasko; Jonathan Graff-Radford; Neill R Graff-Radford; Patrick R Hof; Pierre Krolak-Salmon; Manja Lehmann; Eloi Magnin; Mario F Mendez; Peter J Nestor; Chiadi U Onyike; Victoria S Pelak; Yolande Pijnenburg; Silvia Primativo; Martin N Rossor; Natalie S Ryan; Philip Scheltens; Timothy J Shakespeare; Aida Suárez González; David F Tang-Wai; Keir X X Yong; Maria Carrillo; Nick C Fox Journal: Alzheimers Dement Date: 2017-03-02 Impact factor: 21.566
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Eric Guedj; Andrea Varrone; Ronald Boellaard; Nathalie L Albert; Henryk Barthel; Bart van Berckel; Matthias Brendel; Diego Cecchin; Ozgul Ekmekcioglu; Valentina Garibotto; Adriaan A Lammertsma; Ian Law; Iván Peñuelas; Franck Semah; Tatjana Traub-Weidinger; Elsmarieke van de Giessen; Donatienne Van Weehaeghe; Silvia Morbelli Journal: Eur J Nucl Med Mol Imaging Date: 2021-12-09 Impact factor: 10.057
Authors: Amelia Strom; Leonardo Iaccarino; Lauren Edwards; Orit H Lesman-Segev; David N Soleimani-Meigooni; Julie Pham; Suzanne L Baker; Susan M Landau; William J Jagust; Bruce L Miller; Howard J Rosen; Maria Luisa Gorno-Tempini; Gil D Rabinovici; Renaud La Joie Journal: Brain Date: 2022-04-18 Impact factor: 15.255
Authors: Michael J Firbank; John T O'Brien; Rory Durcan; Louise M Allan; Sally Barker; Joanna Ciafone; Paul C Donaghy; Calum A Hamilton; Sarah Lawley; Jim Lloyd; Gemma Roberts; John-Paul Taylor; Alan J Thomas Journal: J Neurol Date: 2020-10-21 Impact factor: 4.849
Authors: E H Singleton; Y A L Pijnenburg; P Gami-Patel; B D C Boon; F Bouwman; J M Papma; H Seelaar; P Scheltens; L T Grinberg; S Spina; A L Nana; G D Rabinovici; W W Seeley; R Ossenkoppele; A A Dijkstra Journal: Alzheimers Res Ther Date: 2022-01-20 Impact factor: 8.823